Bimzelx (bimekizumab-bkzx) — United Healthcare
non-radiographic axial spondyloarthritis
Initial criteria
- Diagnosis of non-radiographic axial spondyloarthritis
- Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Bimzelx therapy
- Patient is not receiving Bimzelx in combination with another targeted immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
Approval duration
12 months